The IQOS 3 device contains a number of technological advancements, compared to a previously authorized IQOS device, including longer battery life and quicker recharge between uses.
In its decision the FDA noted that:
Commenting on the FDA’s announcement,
“The agency’s decision to authorize IQOS 3 for sale in the
He added, “The order is subject to the same comprehensive commercialization requirements set in the
The IQOS 3 PMTA authorization is independent of the MRTP authorization for the IQOS 2.4 device. PMI expects to file an application seeking a modified exposure marketing order for the IQOS 3 device.
IQOS is available in the U.S. market through an exclusive license with Altria Group, Inc.
T. +41 (0)58 242 4500